pomalidomide / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

27 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pomalidomide / Generic mfg.
NCT02400242: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark P1b data in combination with ricolinostat and dexamethasone for multiple myeloma at ASH 2015
Dec 2015 - Dec 2015: P1b data in combination with ricolinostat and dexamethasone for multiple myeloma at ASH 2015
Active, not recruiting
1a/1b
85
Europe, US
ACY-241, Histone deacetylase inhibitor, Pomalidomide, immunomodulatory agent, Dexamethasone, corticosteriod
Celgene
Multiple Myeloma
01/24
01/24
NCT02616640: A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting
1
114
Europe, Canada, US
Durvalumab, MEDI4736, Pomalidomide, Dexamethasone
Celgene
Multiple Myeloma
11/18
04/24
NCT01728259: First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Terminated
1
18
Canada, US
pomalidomide, CC-4047, bortezomib, LDP 341, MLN341, VELCADE, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, Laboratory Biomarker Analysis
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Light Chain Deposition Disease, Primary Systemic Amyloidosis
10/18
10/18
EQUULEUS, NCT01998971: A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Checkmark Subgroup analysis of MMY1001 at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Subgroup analysis of MMY1001 at ASCO 2018 [screenshot]
Checkmark In combination with KRd for NDMM at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: In combination with KRd for NDMM at ASH 2017 [screenshot]
Checkmark In combination with Kd for relapsed MM at ASH 2017 [screenshot]
More
Completed
1
240
Europe, US
Daratumumab, Velcade, Pomalidomide, Dexamethasone, Melphalan, Prednisone, Thalidomide, Diphenhydramine, Acetaminophen, Carfilzomib, Lenalidomide, Montelukast
Janssen Research & Development, LLC
Multiple Myeloma
01/19
01/24
ChiCTR1900023878: A Randomized, Open-label, Balanced, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence study of Pomalidomide capsules (4 mg) of Qilu Pharmaceutical Co., Ltd. with Imnovid? (pomalidomide) caspules 4 mg of Celgene Europe Limited in Normal, Healthy, Adult Male subjects under fasting conditions.

Not yet recruiting
1
36
 
T / R ;R / T
Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University; the Third Xiangya Hospital, Central South University, Qilu pharmaceutical co. LTD
multiple myeloma
 
 
CPD-DARA, NCT04667663: in Patients With Relapsed/Refractory Multiple Myeloma.

Active, not recruiting
1
20
Europe
Daratumumab, Darzalez, Cyclophosphamide, Pomalidomide, Pomalyst, Imnovid, Dexamethasone
Cancer Trials Ireland, Janssen Pharmaceuticals, Bristol-Myers Squibb
Multiple Myeloma
04/22
04/26
NCT01562405: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
33
US
ACE-011, Sotatercept, Lenalidomide, Revlimid, Dexamethasone, Decadron, Pomalidomide, Pomalyst
Massachusetts General Hospital, Multiple Myeloma Research Consortium
Multiple Myeloma
12/24
06/25
CASE1A17, NCT03143985: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Completed
1
18
US
Vactosertib, TEW-7197, EW7197, EW-7197, Pomalidomide, POM
Koen van Besien
Multiple Myeloma
02/22
09/22
NCT03828292: An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Active, not recruiting
1
15
Japan
Belantamab mafodotin, Bortezomib, Dexamethasone, Pomalidomide
GlaxoSmithKline
Multiple Myeloma
04/23
12/24
MagnetisMM-1, NCT03269136: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Checkmark Efficacy data from MagnetisMM-1 trial for multiple myeloma at ASCO 2022
Jun 2022 - Jun 2022: Efficacy data from MagnetisMM-1 trial for multiple myeloma at ASCO 2022
Checkmark Data from the study for multiple myeloma ASH 2020
Dec 2020 - Dec 2020: Data from the study for multiple myeloma ASH 2020
Checkmark Data from MagnetisMM-1 trial for multiple myeloma
More
Completed
1
101
Canada, US
PF-06863135 monotherapy IV or SC, BCMA-CD3 bispecific antibody, PF-06863135 + dexamethasone, BCMA-CD3 bispecific antibody + dexamethasone, PF-06863135 + lenalidomide, BCMA-CD3 bispecific antibody + lenalidomide, PF-06863135 + pomalidomide, BCMA-CD3 bispecific antibody + pomalidomide
Pfizer
Multiple Myeloma
01/24
01/24
NCT04045795: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Completed
1
56
Europe, Japan, US, RoW
isatuximab SAR650984 IV, Sarclisa, pomalidomide, Pomalyst®, dexamethasone, Decadron®, isatuximab SAR650984 SC, Investigational injector device
Sanofi
Multiple Myeloma
03/24
03/24
NCT03984097: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting
1
50
US
TAK-079, Mezagitamab, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide
Takeda
Multiple Myeloma
02/25
02/25
MajesTEC-2, NCT04722146: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Checkmark MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Dec 2022 - Dec 2022: MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Active, not recruiting
1
140
Europe, US, RoW
Teclistamab, JNJ-64007957, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Janssen Research & Development, LLC
Multiple Myeloma
10/24
02/25
TRIMM-2, NCT04108195: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Active, not recruiting
1
290
Europe, Canada, US
Daratumumab, JNJ-54767414, Darzalex, Talquetamab, JNJ-64407564, Teclistamab, JNJ-64007957, Pomalidomide
Janssen Research & Development, LLC
Multiple Myeloma
09/24
08/25
CAMMA 1, NCT04910568: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
184
Europe, Canada, Japan, US, RoW
Cevostamab, Tocilizumab, Actemra/RoActemra, Pomalidomide, Daratumumab, Dexamethasone
Genentech, Inc., Hoffmann-La Roche
Multiple Myeloma
09/24
07/25
NCT06058689: A Pilot Bioequivalence Study of Pomalidomide

Not yet recruiting
1
10
RoW
Pomalidomide 4 MG Oral Capsule, Pomalyst, Pomalidomide Megalabs
Megalabs
Bioequivalence Study
11/24
03/25
MonumenTAL-2, NCT05050097: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Recruiting
1
182
Europe, US, RoW
Talquetamab, JNJ-64407564, Carfilzomib, Daratumumab SC, Lenalidomide, Pomalidomide
Janssen Research & Development, LLC
Multiple Myeloma
07/25
10/25
SGNBCMA-001, NCT03582033: A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Terminated
1
83
US
SEA-BCMA, dexamethasone, pomalidomide
Seagen Inc.
Multiple Myeloma
11/23
11/23
NCT01198067: Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Active, not recruiting
1
15
US
Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
04/25
04/25
iinnovate-2, NCT05556616: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Active, not recruiting
1
120
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda
Multiple Myeloma
01/24
06/24
NCT02659930: Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Active, not recruiting
1
62
US
liposomal doxorubicin, pomalidomide
National Cancer Institute (NCI)
Kaposi Sarcoma
01/26
01/28
NCT04902443: Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Recruiting
1
54
US
Pomalidomide, Nivolumab
National Cancer Institute (NCI)
Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
12/25
12/26
NCT05556798: A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Recruiting
1
30
US
Belantamab Mafodotin, GSK2857916, Nirogacestat, Pomalidomide
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
10/26
10/26
NCT05828459: First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Recruiting
1
150
Europe
OT-A201, IMids, lenalidomide, pomalidomide, Bevacizumab, Paclitaxel, TBD Compound
Onward Therapeutics
Hematological Malignancy, Solid Tumor
01/27
07/27
LINKER-MM2, NCT05137054: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Recruiting
1
317
Europe, US
Linvoseltamab, REGN5458, Daratumumab, Darzalex®; Darzalex Faspro™, Carfilzomib, Kyprolis®, Lenalidomide, Revlimid®, Bortezomib, Velcade®, Pomalidomide, Imnovid, Pomalyst®, Isatuximab, Sarclisa®, Fianlimab, REGN3767, Cemiplimab, LIBTAYO, Nirogacestat, PF-03084014
Regeneron Pharmaceuticals
Multiple Myeloma
03/27
01/33
NCT05389423: Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Recruiting
1
20
US
Vincristine, Prednisone, Doxorubicin, Etoposide, Pomalidomide, Cyclophosphamide, Rituximab
National Cancer Institute (NCI)
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
06/28
06/32
NCT05259839: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
1
270
Europe, Japan, US, RoW
ABBV-383, Dexamethasone, Lenalidomide, Pomalidomide, Nirogacestat, Daratumumab
TeneoOne Inc.
Relapsed/Refractory Multiple Myeloma
11/28
07/31

Download Options